文献速递妇科

围术期红细胞输注对卵巢癌手术后恢复及长期结局的影响:倾向性评分匹配分析

Impact of perioperative red blood cell transfusion on postoperative recovery and long-term outcome in patients undergoing surgery for ovarian cancer: A propensity score-matched analysis.
PubMed 文献 · Gynecol Oncol · 2019-12-12

倾向性评分匹配后,PRBCT组术后全身炎症指标波动更大(P<0.001)、II级并发症发生率更高(28.4% vs 14.8%)、住院时间更长(10.6天 vs 6.2天)、30天及总再入院率更高(7.1% vs 4.4%和11.2% vs 8.1%,P<0.001),且术后3年总生存率(58.9% vs 74.5%)和无病生存率(39.6% vs 52.3%)显著更低。

要点

  • PRBCT与术后炎症指标波动增大相关(P<0.001)。
  • PRBCT组II级并发症28.4% vs 14.8%,住院10.6天 vs 6.2天。
  • PRBCT组3年OS 58.9% vs 74.5%,DFS 39.6% vs 52.3%。

核心结论

  • PRBCT与卵巢癌初次肿瘤细胞减灭术后炎症指标波动增大、住院时间延长、并发症发生率增高及癌症复发和总死亡率增加显著相关。

主要发现

  • 倾向性匹配后两组临床特征无显著差异。
  • PRBCT组术后全身炎症反应相关指标波动更大(P<0.001)。
  • PRBCT组术后II级并发症发生率28.4% vs 14.8%,住院时间10.6天 vs 6.2天。
  • PRBCT组30天再入院率7.1% vs 4.4%,总再入院率11.2% vs 8.1%(P<0.001)。
  • PRBCT组术后3年OS 58.9% vs 74.5%,DFS 39.6% vs 52.3%,均显著低于未接受PRBCT组。

关键数值与推荐

  • PRBCT组术后II级并发症发生率28.4%,未接受PRBCT组14.8%。
  • PRBCT组住院时间10.6天,未接受PRBCT组6.2天。
  • PRBCT组30天再入院率7.1%,未接受PRBCT组4.4%;总再入院率11.2% vs 8.1%(P<0.001)。
  • PRBCT组术后3年OS 58.9%,未接受PRBCT组74.5%;DFS 39.6% vs 52.3%。

临床怎么用

  • 原文未提供临床实践指导。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The impact of perioperative red blood cell transfusion (PRBCT) on cancer survival has remained controversial. METHODS: We conducted a retrospective study in patients undergoing primary debulking surgery (PDS) for ovarian cancer between January 2013 and December 2017. The patients were divided into two groups based on whether they received PRBCT. Clinical characteristics were compared between groups. After propensity score matching, perioperative systemic inflammation-based scores, quality of recovery, postoperative outcomes, disease-free survival (DFS), and overall survival (OS) were compared between groups. Univariate and multivariable Cox proportional hazard models were used to evaluate the association between covariates and survival outcomes. RESULTS: A total of 1037 patients were enrolled in this study, and 31.7% of patients received PRBCT. After propensity matching, there was no significant difference in the clinical characteristics between groups. Patients receiving PRBCT had more postoperative fluctuations in systemic inflammatory response-related indicators (P < 0.001), a higher incidence of postoperative grade II complications (28.4% vs. 14.8%), a longer length of stay (10.6 d vs. 6.2 d) and higher 30-day and total readmission rates (7.1% vs. 4.4% and 11.2% vs. 8.1%, P < 0.001, respectively) than patients who did not receive PRBCT. The OS and DFS rates 3 years after surgery were significantly lower in the patients receiving PRBCT than in patients not receiving PRBCT (58.9% vs. 74.5%, 39.6% vs. 52.3%). CONCLUSIONS: PRBCT was significantly associated with more fluctuations in systemic inflammatory indicators, a prolonged length of stay, higher postoperative complication rates and increased cancer recurrence and overall mortality in ovarian cancer patients undergoing PDS.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Zhang H, Wu X, Xu Z, et al. Impact of perioperative red blood cell transfusion on postoperative recovery and long-term outcome in patients undergoing surgery for ovarian cancer: A propensity score-matched analysis. Gynecol Oncol. 2019. PMID: 31839344. doi:10.1016/j.ygyno.2019.12.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。